Skip to content

Startup & venture capital news

SRTD Biotech raises EUR 31.5m for targeted RNA therapies

Mérieux leads with NRW.BANK and Boehringer’s venture fund as co-leads.

By /

LinkedInX
SRTD Biotech: SRTD Biotech raises EUR 31.5m for targeted RNA therapies

SRTD Biotech raised EUR 31.5 million in an oversubscribed seed round led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Venture Fund. Lilly Ventures, HTGF and Anobis Asset also participated. The Jülich company develops selectively expressed RNA therapies designed to activate therapeutic payloads inside targeted diseased cells while limiting activity in healthy tissue. The capital will fund preclinical development across oncology, autoimmune disease and fibrosis programmes towards regulatory applications. SRTD also appointed Matthias Alder as chief executive following the financing. The technology remains preclinical, and no approved treatment or completed human clinical result was announced.

Keep reading

More Funding

All stories